Genetic Polymorphism at BCL2 as a predictor for R-CHOP efficacy in patients with diffuse large B-cell lymphoma.
|Authors||Morteza Bashash, Joseph M Connors, Randy D Gascoyne, Barbara Meissner, Johanna M Schuetz, Stephen Leach, Graham W Slack, Brian R Berry, Howard Hu, Laurie H Sehn, Angela R Brooks-Wilson & John J Spinelli|
|Abstract||In this study, we examine the usefulness of germline BCL2 singlenucleotide polymorphisms (SNP) in identifying low and high risk patients. Our initial study identified two constitutional BCL2 SNPs significantly associated with survival of DLBCL patients treated with R-CHOP. We independently examined the impact of both SNPs in an independent replication set and the association with survival for one of the SNPs, rs7226979, was confirmed. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm and accounts for about 30-40% of non-Hodgkin lymphomas. The prognosis of patients with DLBCL has improved for all ages and both sexes in recent years. One of the reasons for this survival improvement is the addition of rituximab to conventional CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. From March 1, 2001, the British Columbia (BC) Cancer Agency implemented this approach by recommending the combination of CHOP and rituximab (R-CHOP) for all newly diagnosed patients with DLBCL, regardless of age, in the province of BC .|
|Journal Name and Citation||
Haematologica. 2017 Feb 2. pii: haematol.2016.159087. doi: 10.3324/haematol.2016.159087. [Epub ahead of print]
|Date of Publication||2017/02/02|